RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of doxorubicin plus estramustine in
treating patients with metastatic recurrent prostate cancer that does not respond to hormone
OBJECTIVES: I. Estimate the maximum tolerated dose of weekly intravenous doxorubicin (DOX)
that can be given in combination with oral estramustine (EM) in patients with metastatic
prostate cancer refractory to treatment with hormonal agents. II. Assess the frequency of
expression of the multidrug resistance phenotype in biopsy specimens from these patients.
III. Assess the response to DOX/EM in these patients.
OUTLINE: 2-Drug Combination Chemotherapy. Doxorubicin, DOX, NSC-123127; Estramustine, EM,
PROJECTED ACCRUAL: Three to 18 patients will be entered.
DISEASE CHARACTERISTICS: Biopsy proven metastatic prostate cancer Biopsy requirement
waived at principal investigator's discretion if new disease site technically inaccessible
and PSA elevated Recurrent disease following orchiectomy, estrogen, or
gonadotropin-releasing hormone agonist therapy If previously irradiated: Progressive
disease outside prior radiotherapy field required No brain metastases
PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Hematopoietic:
Not specified Hepatic: Bilirubin no greater than 1.5 mg/dL ALT/AST less than 3 times
greater than normal Renal: Not specified Cardiovascular: Left ventricular ejection
fraction at least 45% No NYHA class III/IV status No unstable angina Other: No Crohn's
disease, ulcerative colitis, or other inflammatory bowel syndrome
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior
doxorubicin or estramustine Endocrine therapy: See Disease Characteristics At least 30
days since flutamide Estrogen or gonadotropin-releasing hormone agonists discontinued
prior to treatment Radiotherapy: At least 6 weeks since radiotherapy Surgery: Not